(260 days)
TheraCal DC is indicated for use for:
-
- Pulpotomy
-
- Temporary filling material
-
- Repair of root perforations
- Repair of furcation perforations 4.
-
- Repair of perforating internal and external resorptions
-
- Root-end filling in endodontic surgery
-
- Pulp exposures (direct pulp capping)
-
- Protective liner (Indirect Pulp Capping) and Base for use under a variety of substrates
TheraCal DC is a biocompatible, dual-cured, resin-modified calcium silicate that is used to treat damaged dentin in both the crown and the root. TheraCal DC's precise placement allows its use in all deep cavity preparations and endodontic repairs. The dual-cure set permits immediate placement and condensation of the restorative material. Its proprietary formulation allows for a command set with a light curing unit while maintaining ease of placement due to its thixotropic properties.
Here's a breakdown of the acceptance criteria and study information for the TheraCal DC device, extracted from the provided text:
Important Note: The provided document is a 510(k) summary for a dental material (TheraCal DC), not a software or AI-driven medical device. Therefore, many of the requested categories like "test set size," "ground truth experts," "adjudication method," "MRMC study," and "standalone performance" are not applicable in the context of this device and its regulatory submission. The information below reflects what is available in the document for a physical material.
1. Table of Acceptance Criteria and Reported Device Performance
| Physical/Mechanical Property | Acceptance Criteria (Implied / Comparator) | Reported Device Performance for TheraCal DC |
|---|---|---|
| Flexural Strength | Comparable to or greater than predicate devices | Greater than the predicate devices |
| Dimetral Tensile Strength | Comparable to or greater than predicate devices | Greater than the predicate devices |
| Working Time | Met design control inputs | Met the design control inputs |
| Bond Strength (Shear) | Comparable to or greater than predicate devices | Greater than the predicate devices |
| Radiopacity (ISO 4049:2009 7.14) | Meets ISO requirements (1 mm > 1mm of alumina) | Meets the ISO requirements |
| Water Sorption (ISO 4049:2009) | Meets ISO 4049 requirements | Meets the ISO 4049 requirements |
| Water Solubility (ISO 6876:2012) | Meets ISO 6876 requirements | Meets the ISO 6876 requirements |
| Calcium Release | Equivalent to predicate devices | Equivalent to the predicate devices |
| pH Testing | Equivalent to predicate devices | Equivalent to the predicate devices |
| Biocompatibility (ISO 7405:2008 & ISO 10993-1:2009) | Meets requirements of testing | Met the requirements of the testing |
2. Sample Size Used for the Test Set and Data Provenance
- Sample Size for Test Set: Not specified. This document summarizes and compares physical/mechanical properties and biocompatibility, which typically involve laboratory tests on material samples rather than a "test set" in the sense of patient data.
- Data Provenance: Not specified. The tests are "in-house test method" or reference ISO/ANSI/ADA standards, suggesting laboratory testing. No information on country of origin or retrospective/prospective nature is relevant for this type of device.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
- Number of Experts: Not applicable. Ground truth for material properties is established through standardized laboratory testing methods, not expert consensus on interpretations.
- Qualifications of Experts: Not applicable.
4. Adjudication Method for the Test Set
- Adjudication Method: Not applicable. Material property testing does not typically involve adjudication.
5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study Was Done, If So, What Was the Effect Size of How Much Human Readers Improve with AI vs Without AI Assistance
- MRMC Study: No, this is not an AI-driven device.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
- Standalone Study: No, this is not an AI-driven device.
7. The Type of Ground Truth Used
- Type of Ground Truth: The "ground truth" for the performance data mentioned is established through standardized laboratory test methods (e.g., ISO, ANSI/ADA standards) and direct comparison to legally marketed predicate devices. For biocompatibility, it's defined by compliance with ISO standards (ISO 7405:2008 and ISO 10993-1:2009).
8. The Sample Size for the Training Set
- Sample Size for Training Set: Not applicable. There is no "training set" in the context of a physical dental material. The material is developed and formulated based on scientific principles and then tested against established standards and predicate devices.
9. How the Ground Truth for the Training Set Was Established
- How Ground Truth for Training Set Was Established: Not applicable.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other. The profiles are simple and abstract, with only the outlines of the faces visible.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
August 4, 2015
Bisco Inc. Ms. Michelle Schiltz-Taing Regulatory Affairs Product Registration Manager 1100 West Irving Park Road Schaumburg, Illinois 60193
Re: K143292
Trade/Device Name: TheraCal DC Regulation Number: 21 CFR 872.3250 Regulation Name: Calcium Hydroxide Cavity Liner Regulatory Class: II Product Code: EJK Dated: June 24, 2015 Received: June 26, 2015
Dear Ms. Schiltz-Taing:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{1}------------------------------------------------
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely vours.
Tina
Kiang -S
for Erin I. Keith, M.S. Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
510 (k) Number (if known): _ K143292
Device Name: _ TheraCal DC
Indications for Use:
TheraCal DC is indicated for use for:
-
- Pulpotomy
-
- Temporary filling material
-
- Repair of root perforations
- Repair of furcation perforations 4.
-
- Repair of perforating internal and external resorptions
-
- Root-end filling in endodontic surgery
-
- Pulp exposures (direct pulp capping)
-
- Protective liner (Indirect Pulp Capping) and Base for use under a variety of substrates
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
{3}------------------------------------------------
Image /page/3/Picture/0 description: The image shows the logo for BISCO. The logo consists of a series of five interconnected geometric shapes in red and blue, arranged horizontally. Below the shapes is the word "BISCO" in a bold, sans-serif font, with the letters in gray and black.
510 (k) SUMMARY
| Applicant: |
|---|
| ------------ |
Bisco, Inc. 1100 W. Irving Park Road Schaumburg IL, 60193
Contact Person:
Michelle Schiltz-Taing Tel: 847-534-6146 Fax: 847-534-6146
03 August 2015
Date Prepared:
Trade Name: Common Name: Product Code: Classification/Name:
TheraCal DC Dual-Cured Resin-Modified Calcium Silicate Pulp Protectant EJK Liner, Cavity, Calcium Hydroxide Class II per 21 CFR 872.3250
Predicate Devices:
TheraCal DC is substantially equivalent to:
TheraCal LC by Bisco Inc. K063237 Primary Predicate: Reference Predicates: BioDentine by Septodont K140132 RMGI Low Viscosity (believed to be Activa) by Pulpdent K123265 Pro Root MTA by Dentsply K142178
TheraCal DC is indicated for use for:
-
- Pulpotomy
-
- Temporary Filling Material
-
- Repair of Root Perforations
-
- Repair of Furcation Perforations
-
- Repair of Perforating Internal and External Resorptions
-
- Root-End Filling in Endodontic Surgery
-
- Pulp Exposures (Direct Pulp Capping)
-
- Protective Liner (Indirect Pulp Capping) and Base for Use Under a Variety of Substrates
BISCO, Inc. 1100 W. Irving Park Road Schaumburg, IL 60193 U.S.A.
{4}------------------------------------------------
Image /page/4/Picture/0 description: The image shows the logo for BISCO. The logo consists of five connected hexagons in a row, with the two outer hexagons being red and the middle hexagon being light blue. The word "BISCO" is written in large, bold, gray letters below the hexagons.
510 (k) SUMMARY (continued)
The indications for use of TheraCal DC are the same as those for its predicates and are summarized in the table below:
| TheraCal LCK063237 | ActivaK123265 | ProRoot MTAK142178 | BioDentineK140132 | TheraCal DC |
|---|---|---|---|---|
| 1. Liner2. Pulp Capping Agent | Pulpdent RMGI Low viscosity is a resin-modified glass ionomer preparation used by dental professionals as a liner, base or luting material in dental restorations | root end filling material for the repair of repair of root canals as an apical plug during apexification for the repair of root perforations during root canal therapy or as a consequence of internal resorption as a pulp capping material pulpotomy of primary teeth in the child (ages >2-12 years) and adolescent (ages >12-21 years) pediatric patient populations | Biodentine is indicated to be used:In the crown:-permanent dentine restoration under composites or inlay/onlay-temporary dentine-enamel restoration-restoration of deep and/or large coronal carious lesions (sandwich technique)-restoration of cervical radicular lesions.-pulp capping.-pulpotomy.In the root:-repair of root perforations-repair of furcation perforations-repair of perforating | TheraCal DC is indicated for use for:1. Pulpotomy2. Temporary filling material3. Repair of root perforations4. repair of furcation perforations5. repair of perforating internal and external resorptions6. root-end filling in endodontic surgery7. pulp exposures (direct pulp capping)8. Protective liner (indirect pulp capping) and base for use under a variety of substrates |
Description of Applicant Device:
TheraCal DC is a biocompatible, dual-cured, resin-modified calcium silicate that is used to treat damaged dentin in both the crown and the root. TheraCal DC's precise placement allows its use in all deep cavity preparations and endodontic repairs. The dual-cure set permits immediate placement and condensation of the restorative material. Its proprietary formulation allows for a command set with a light curing unit while maintaining ease of placement due to its thixotropic properties.
{5}------------------------------------------------
Image /page/5/Picture/0 description: The image shows the logo for BISCO. The logo features a series of connected, three-dimensional hexagonal shapes in red and blue. Below the shapes is the word "BISCO" in large, bold, gray letters with a glossy effect.
Technological Characteristics:
All components of TheraCal DC are based upon industry standard chemistry. Comparisons of the chemical composition of TheraCal DC to the predicates are provided in the following table:
| Chemical Composition | TheraCal LCK063237 | ActivaK123265 | TheraCal DC |
|---|---|---|---|
| Filler | Portland Cement | Amorphous Silica | Portland Cement |
| Resin Composition | Hydrophilic resin tofacilitate calcium release | Blend of diurethane and othermethacrylates with modifiedpolyacrylic acid | Hydrophilic resin tofacilitate calcium release |
| Method of polymerization | Light-Cure | Dual-Cure | Dual-Cure |
| Method of Application | Bonding agent not required | Bonding agent not required | Bonding agent not required |
| Ions Released | Calcium and hydroxide | Calcium, phosphate, and fluoride | Calcium and hydroxide |
| Physical / Mechanical PropertyComparison | TheraCal LCK063237 | ActivaK123265 | BioDentineK140132 | TheraCal DC |
|---|---|---|---|---|
| Radiographic Appearance(ISO 4049:2009 7.14) | Radiopaque | Radiopaque | Radiopaque | Radiopaque |
| Ions Released | Calcium releasing | Fluoridecontaining | Calciumreleasing | Calcium releasing |
| pH | basic | Not reported | basic | basic |
The difference in chemical composition as compared to the primary predicate is the addition of industry standard chemicals to make TheraCal DC dual-curable. A reference predicate has been provided that is also dual-cured (Activa).
Performance Data:
The following physical/mechanical properties of TheraCal DC were tested: flexural strength (ISO 4049:2009), compressive strength (ANSI/ADA Spec. No. 27:1993 Appendix A2), dimetral tensile strength (in-house test method), working time (in-house test method), bond strength (inhouse test method), radiopacity (ISO 4049:2009), water sorption and solubility (ISO 4049:2009 and ISO 6876:2012), calcium release (in-house test method), and pH (in-house test method). An evaluation of biocompatibility of TheraCal DC was conducted using ISO 7405:2008 and ISO 10993-1:2009. Direct comparison testing demonstrates that TheraCal DC is similar to or greater than the predicate devices.
| Physical / Mechanical Property | TheraCal DC |
|---|---|
| Flexural Strength | TheraCal DC is greater than the predicate devices |
| Dimetral Tensile Strength | TheraCal DC is greater than the predicate devices |
| Working Time | Not compared to predicate devices; met the design control inputs |
| Bond Strength | TheraCal DC shear bond strength is greater than the predicate devices |
| Radiopacity | Meets the ISO requirements (1 mm of TheraCal DC > 1mm of alumina) |
| Water Sorption & Solubility | TheraCal DC meets the ISO 4049 requirements for water sorption |
| TheraCal DC meets the ISO 6876 requirements for water solubility | |
| Calcium Release | TheraCal DC is equivalent to the predicate devices |
| pH Testing | TheraCal DC is equivalent to the predicate devices |
{6}------------------------------------------------
Image /page/6/Picture/0 description: The image shows the BISCO company logo. The logo consists of five connected hexagons, with the first two being red, the third being blue, and the last two being red. Below the hexagons is the word "BISCO" in a bold, sans-serif font, with the top half of the letters being gray and the bottom half being black.
It is concluded from the evaluation and the results of the cytotoxicity study that TheraCal DC meets the requirements of the testing.
Conclusion:
It is concluded that the information supplied in this submission has demonstrated that TheraCal DC is substantially equivalent to the legally marketed predicate devices because:
- . The indications for use are the same to the listed predicates,
- . The chemical composition, method of application and method of polymerization is similar to the primary and reference predicate devices.
- . Physical properties are equivalent to the predicates.
- The requirements of the biological testing were met. ●
§ 872.3250 Calcium hydroxide cavity liner.
(a)
Identification. A calcium hydroxide cavity liner is a device material intended to be applied to the interior of a prepared cavity before insertion of restorative material, such as amalgam, to protect the pulp of a tooth.(b)
Classification. Class II.